BCIQ Profiles

Company Profile Report
0902 BTS12 UK fresh start
BioCentury

Back to School

MHRA seizes opportunity to reshape expedited approval

Newly independent, MHRA leapfrogs FDA, EMA pathways by integrating regulatory, reimbursement throughout the process

Newly independent, MHRA leapfrogs FDA and EMA pathways by integrating regulatory and reimbursement throughout the process.

Sep 2, 2021 | 1:10 PM GMT

The U.K.’s exit from the EU has afforded its MHRA a fresh start in creating an expedited approval pathway that goes beyond what FDA or EMA can offer: integrating market access, clinical trial and real-world evidence organizations directly into the process through the Innovative Licensing and Access Pathway. 

Since MHRA became an independent regulator following the U.K.’s departure from the EU on Jan. 1, 2021, the agency has created the next

Read the full 1177 word article

How to gain access

Continue reading with a
two-week free trial.